Latest News
News
FDA approves nivolumab for HCC patients
Approval of nivolumab for HCC was based on tumor response rate and durability of response from the phase 1/2 Checkmate 040 trial.
Conference Coverage
GEICAM/2006-10: Adjuvant fulvestrant/anastrozole role in early breast cancer uncertain
MADRID – Complete estrogen blockade showed no improvement in survival over anastrozole alone, although the trial was underpowered.
From the Journals
Primary care deficient in cancer survivor care
Primary care physicians falling short with cancer survivors.
From the Journals
Battling physician burnout delivers monetary benefits for health care organizations
Organizations can combat physician burnout, and the effort is worthwhile, as well as morally and ethically important.
Conference Coverage
‘Very daring study’ of neoadjuvant AI/CDKi combo in early BC is hypothesis generating
The nonchemo neoadjuvant regimen offered a slightly higher residual cancer burden prior to surgery, but a significantly better safety profile than...
Feature
Residents getting unprecedented attention from employers
Survey shows that “the search for newly trained physicians is on the verge of becoming a feeding frenzy.”
From the Journals
Motesanib flops again in lung cancer
The investigational oral VEGF inhibitor did not significantly improve progression-free or overall survival when added to paclitaxel and...
Conference Coverage
IN.PACT Global: Promising 2-year data for drug-coated balloon performance for femoropopliteal PAD
Drug-coated balloon shows promising 2-year results for treating fempop PAD.
Feature
Docs, insurers condemn latest ‘repeal and replace’ plan
The GOP faces a tough road for passing the Graham-Cassidy proposal.
Conference Coverage
No difference in survival between x-ray or CT NSCLC follow-up
MADRID – CT scans show no real advantage over x-rays in overall survival during follow-up after resection, although they may catch other cancers...
Conference Coverage
RANGE: Small PFS edge in urothelial cancer with VEGFR-2 inhibitor
MADRID – PFS was 4.07 months for patients with advanced urothelial carcinoma randomized to ramucirumab and docetaxel, compared with 2.76 months...